Pharmacological effect of Ridaura
The preparation of gold with the anti-inflammatory and immunomodulatory activity. The mechanism of action is probably due to the influence on immune processes.
Pharmacokinetics Ridaura
After ingestion Ridaura incompletely absorbed from the gastrointestinal tract, absorption of gold is about 25%. Gold is released from auranofin, bound to plasma proteins and erythrocytes. After 2-3 months of treatment Css gold in the blood is about 0.7 mg / ml. In equilibrium, the average end-T1 / 2 was 26 days, and biological T1 / 2 – 81 Delay of gold in the tissues and the total accumulation is less than i / m administration of gold. Gold from auranofin penetrating the synovial fluid.
Most of the dose excreted in the feces Ridaura due to low absorption from the gastrointestinal tract. About 60% of adsorbed gold from auranofin is excreted in the urine, the remainder – with the feces.
Indications Ridaura
Basic therapy of rheumatoid arthritis.
Dosing regimen Ridaura
Adults – to 6 mg (1 or 2 doses). When clinical failure admission within 3 months the dose can be increased to 9 mg, provided that favorable results are not achieved within the next 3 months, treatment should be discontinued.
Side effects of Ridaura
From the digestive system: diarrhea, stomach pain, rash, itching, sores, rarely – liver function abnormalities.
From the hematopoietic system: rarely – anemia, leukopenia, very rarely – thrombocytopenia.
With the urinary system: rarely – proteinuria, impaired renal function.
Other: conjunctivitis, rarely – Allergic reactions such as skin rashes.
Contra Ridaura
Progressive kidney disease, liver disease in the active phase; indicate a history of violations of bone marrow hematopoiesis, bone marrow aplasia, severe blood disease, severe chronic forms of dermatitis; indicate a history of necrotizing enterocolitis, caused by the action of gold indicate a history of pulmonary fibrosis caused by action of gold, pregnancy, lactation, infancy, increased sensitivity to drugs of gold, increased sensitivity to drugs of heavy metals.
Application of pregnancy and breastfeeding
Contraindicated during pregnancy and lactation.
Cautions
Before starting therapy Ridaura should undertake the following laboratory tests: hemoglobin, platelet count, liver transaminase activity, concentration of urea, creatinine, amount of protein in the urine. Within 1 year of treatment needed every month to check the pattern of peripheral blood and protein in urine. During the 2-year treatment, these studies can be carried out every 2-3 months. When proteinuria over 1 g / discontinue use.
